Cargando…

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma

Sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). However, there is no evidence for a response of different target lesions to sorafenib administration. Therefore, we aimed to evaluate the effect of sorafenib on various aHCC target lesions. The outcomes of sorafenib treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Song-Fong, Chong, Sio-Wai, Huang, Chun-Wei, Hsu, Heng-Yuan, Pan, Kuang-Tse, Hung, Chien-Fu, Wu, Tsung-Han, Lee, Chao-Wei, Hsieh, Chia-Hsun, Wang, Ching-Ting, Chai, Pei-Mei, Yu, Ming-Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496215/ https://www.ncbi.nlm.nih.gov/pubmed/36140381 http://dx.doi.org/10.3390/biomedicines10092277

Ejemplares similares

Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma
por: Huang, Chun-Wei, et al.
Publicado: (2022)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma
por: Yu, Ming-Chin, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma
por: Chan, Wen‐Hui, et al.
Publicado: (2016)

Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study
por: Chan, Wen-Hui, et al.
Publicado: (2019)

Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma
por: Lee, Wei‐Chen, et al.
Publicado: (2020)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma
por: Tsai, Hung-Wen, et al.
Publicado: (2023)

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Effect of the Kinesio tape to muscle activity and vertical jump performance in healthy inactive people
por: Huang, Chen-Yu, et al.
Publicado: (2011)

Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis
por: Que, Jenny, et al.
Publicado: (2020)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2021)

Prophylactic Administration of Fucoidan Represses Cancer Metastasis by Inhibiting Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinases (MMPs) in Lewis Tumor-Bearing Mice
por: Huang, Tse-Hung, et al.
Publicado: (2015)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib
por: Hsieh, Ming-Han, et al.
Publicado: (2020)

Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma
por: Nojiri, Shunsuke, et al.
Publicado: (2012)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
por: Lu, Meng-Chuan, et al.
Publicado: (2023)

Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma
por: Liao, Yi-Jen, et al.
Publicado: (2020)

Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study
por: Kok, Victor C., et al.
Publicado: (2019)

The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality
por: Chiang, Chien-Hsieh, et al.
Publicado: (2016)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance
por: Chang, Yung-Sheng, et al.
Publicado: (2022)

Beneficial effects of early empirical administration of appropriate antimicrobials on survival and defervescence in adults with community-onset bacteremia
por: Lee, Ching-Chi, et al.
Publicado: (2019)

Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Prognostic Effects of Delayed Administration of Appropriate Antimicrobials in Bacteraemic Adults Initially Presenting with Various Body Temperatures
por: Ho, Ching-Yu, et al.
Publicado: (2022)

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
por: Peng, Tzu-Rong, et al.
Publicado: (2021)

Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma
por: Huang, Yao-Kuang, et al.
Publicado: (2017)

Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma
por: Yuan, Wei, et al.
Publicado: (2021)

Deep Brain Stimulation of the Pedunculopontine Tegmental Nucleus Renders Neuroprotection through the Suppression of Hippocampal Apoptosis: An Experimental Animal Study
por: Praveen Rajneesh, Chellappan, et al.
Publicado: (2020)

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure
por: Cheng, Tsung-Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m3m0d9uk3616gdimt7rlsb9cka